메뉴 건너뛰기




Volumn 15, Issue 5, 2012, Pages 664-673

Switching from originator brand medicines to generic equivalents in selected developing countries: How much could be saved?

Author keywords

affordability; cost; developing countries; generics; medicines; originator brands; pharmaceuticals; savings

Indexed keywords

ACICLOVIR; AMITRIPTYLINE; ATENOLOL; ATORVASTATIN; BECLOMETASONE; CAPTOPRIL; CARBAMAZEPINE; CEFTRIAXONE; CIPROFLOXACIN; COTRIMOXAZOLE; FLUOXETINE; GENERIC DRUG; GLIBENCLAMIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; OMEPRAZOLE; RANITIDINE; SALBUTAMOL; SIMVASTATIN;

EID: 84864589917     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2012.04.004     Document Type: Article
Times cited : (120)

References (61)
  • 1
    • 14644444077 scopus 로고    scopus 로고
    • World Health Organization World Health Organization Geneva, Switzerland
    • World Health Organization The World Medicines Situation 2004 World Health Organization Geneva, Switzerland
    • (2004) The World Medicines Situation
  • 2
    • 58149522302 scopus 로고    scopus 로고
    • Medicine prices, availability, and affordability in 36 developing and middle-income countries: A secondary analysis
    • A. Cameron, M. Ewen, D. Ross-Degnan Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis Lancet 373 2009 240 249
    • (2009) Lancet , vol.373 , pp. 240-249
    • Cameron, A.1    Ewen, M.2    Ross-Degnan, D.3
  • 4
    • 58149505950 scopus 로고    scopus 로고
    • Non-evidence-based policy: How effective is China's new cooperative medical scheme in reducing medical impoverishment?
    • W. Yip, W. Hsiao Non-evidence-based policy: how effective is China's new cooperative medical scheme in reducing medical impoverishment? Soc Sci Med 68 2009 201 209
    • (2009) Soc Sci Med , vol.68 , pp. 201-209
    • Yip, W.1    Hsiao, W.2
  • 7
    • 67649535214 scopus 로고    scopus 로고
    • Availability, price and affordability of asthma medicines in five Indian states
    • A. Kotwani Availability, price and affordability of asthma medicines in five Indian states Int J Tuberc Lung Dis 13 2009 574 579
    • (2009) Int J Tuberc Lung Dis , vol.13 , pp. 574-579
    • Kotwani, A.1
  • 8
    • 70149119777 scopus 로고    scopus 로고
    • Insights for policy-makers from a medicine price survey in Rajasthan
    • A. Kotwani, N. Gurbani, S. Sharma Insights for policy-makers from a medicine price survey in Rajasthan Ind J Med Res 129 2009 451 454
    • (2009) Ind J Med Res , vol.129 , pp. 451-454
    • Kotwani, A.1    Gurbani, N.2    Sharma, S.3
  • 10
    • 34147164051 scopus 로고    scopus 로고
    • The availability and affordability of selected essential medicines for chronic diseases in six low- and middle-income countries
    • S. Mendis, K. Fukino, A. Cameron The availability and affordability of selected essential medicines for chronic diseases in six low- and middle-income countries Bull World Health Org 85 2007 279 287
    • (2007) Bull World Health Org , vol.85 , pp. 279-287
    • Mendis, S.1    Fukino, K.2    Cameron, A.3
  • 11
    • 33947656506 scopus 로고    scopus 로고
    • Evaluating drug prices, availability, affordability, and price components: Implications for access to drugs in Malaysia
    • Z.U.D. Babar, M.I.M. Ibrahim, H. Singh Evaluating drug prices, availability, affordability, and price components: implications for access to drugs in Malaysia PLoS Med 4 2007 e82
    • (2007) PLoS Med , vol.4 , pp. 82
    • Babar, Z.U.D.1    Ibrahim, M.I.M.2    Singh, H.3
  • 12
    • 80054818181 scopus 로고    scopus 로고
    • Medicine expenditures annex
    • (3rd ed.) World Health Organization Geneva, Switzerland [Accessed November 8, 2011]
    • Y. Lu, P. Hernandez, D. Abegunde, T. Edejer Medicine expenditures annex The World Medicines Situation 2011 (3rd ed.) 2011 World Health Organization Geneva, Switzerland http://www.who.int/medicines/areas/policy/world-medicines- situation/en/index.html [Accessed November 8, 2011]
    • (2011) The World Medicines Situation 2011
    • Lu, Y.1    Hernandez, P.2    Abegunde, D.3    Edejer, T.4
  • 13
    • 0006825962 scopus 로고    scopus 로고
    • Public-Private Roles in the Pharmaceutical Sector - Implications for Equitable Access and Rational Drug Use
    • World Health Organization World Health Organization Geneva, Switzerland
    • World Health Organization Public-Private Roles in the Pharmaceutical Sector - Implications for Equitable Access and Rational Drug Use Health Economics and Drugs Series, No. 005 1997 World Health Organization Geneva, Switzerland
    • (1997) Health Economics and Drugs Series, No. 005
  • 15
    • 79954971455 scopus 로고    scopus 로고
    • The International Bank for Reconstruction and Development/The World Bank Washington, DC
    • A. Seiter A Practical Approach to Pharmaceutical Policy 2010 The International Bank for Reconstruction and Development/The World Bank Washington, DC
    • (2010) A Practical Approach to Pharmaceutical Policy
    • Seiter, A.1
  • 16
    • 2942561779 scopus 로고    scopus 로고
    • World Health Organization World Health Organization Geneva, Switzerland
    • World Health Organization How to Develop and Implement a National Drug Policy 2001 World Health Organization Geneva, Switzerland
    • (2001) How to Develop and Implement A National Drug Policy
  • 17
    • 77956792344 scopus 로고    scopus 로고
    • Quantifying the impoverishing effects of purchasing medicines: A cross-country comparison of the affordability of medicines in the developing world
    • L. Niens, A. Cameron, E. van de Poel Quantifying the impoverishing effects of purchasing medicines: a cross-country comparison of the affordability of medicines in the developing world PLoS Med 7 2010 1 8
    • (2010) PLoS Med , vol.7 , pp. 1-8
    • Niens, L.1    Cameron, A.2    Van De Poel, E.3
  • 18
    • 84864588746 scopus 로고    scopus 로고
    • Use of automated claims data in the Kyrgyzstan outpatient drug benefit program to evaluate medicine pricing trends plus access and equity among beneficiaries: Presentation at ICIUM 2004
    • In: Faden L, Vialle-Valentin C, Ross-Degnan D, Wagner A. Active pharmaceutical management strategies of health insurance systems to improve cost-effective use of medicines in low- and middle-income countries: a systematic review of current evidence
    • A. Ibraimova, C. Cashin, B. Waning Use of automated claims data in the Kyrgyzstan outpatient drug benefit program to evaluate medicine pricing trends plus access and equity among beneficiaries: presentation at ICIUM 2004 www.icium.org/icium2004/resources/ppt/O AC121.ppt. In: Faden L, Vialle-Valentin C, Ross-Degnan D, Wagner A. Active pharmaceutical management strategies of health insurance systems to improve cost-effective use of medicines in low- and middle-income countries: a systematic review of current evidence Health Pol 100 2011 134 143
    • (2011) Health Pol , vol.100 , pp. 134-143
    • Ibraimova, A.1    Cashin, C.2    Waning, B.3
  • 19
    • 67649273394 scopus 로고    scopus 로고
    • Organization for Economic Co-operation and Development Organization for Economic Co-operation and Development Paris, France
    • Organization for Economic Co-operation and Development Pharmaceutical Pricing Policies in a Global Market OECD Health Policy Studies 2008 Organization for Economic Co-operation and Development Paris, France
    • (2008) Pharmaceutical Pricing Policies in A Global Market OECD Health Policy Studies
  • 23
    • 79551645071 scopus 로고    scopus 로고
    • Getting better value from the NHS drugs budget
    • J.C. Moon, A.S. Flett, B.B. Godman Getting better value from the NHS drugs budget BMJ 341 2010 c6449
    • (2010) BMJ , vol.341 , pp. 6449
    • Moon, J.C.1    Flett, A.S.2    Godman, B.B.3
  • 24
    • 66949137185 scopus 로고    scopus 로고
    • European Commission Directorate General Enterprise and Industry Brussels [Accessed May 3, 2011]
    • J. Espin, J. Rovira Analysis of Differences and Commonalities in Pricing and Reimbursement Systems in Europe 2007 European Commission Directorate General Enterprise and Industry Brussels http://ec.europa.eu/enterprise/sectors/ healthcare/files/docs/study-pricing-2007/andalusian-school-public-health-report- pricing-2007-en.pdf [Accessed May 3, 2011]
    • (2007) Analysis of Differences and Commonalities in Pricing and Reimbursement Systems in Europe
    • Espin, J.1    Rovira, J.2
  • 26
    • 77952847455 scopus 로고    scopus 로고
    • Measuring medicine prices in Peru: Validation of key aspects of WHO/HAI survey methodology
    • J.M. Madden, E. Meza, M. Ewen Measuring medicine prices in Peru: validation of key aspects of WHO/HAI survey methodology Rev Panam Salud Publica 27 2010 291 299
    • (2010) Rev Panam Salud Publica , vol.27 , pp. 291-299
    • Madden, J.M.1    Meza, E.2    Ewen, M.3
  • 27
    • 63149105185 scopus 로고    scopus 로고
    • World Health Organization, Health Action International (2nd ed.) World Health Organization and Health Action International Geneva, Switzerland [Accessed May 3, 2011]
    • World Health Organization, Health Action International Measuring Medicine Prices, Availability, Affordability and Price Components (2nd ed.) 2008 World Health Organization and Health Action International Geneva, Switzerland http://www.haiweb.org/medicineprices/manual/documents.html [Accessed May 3, 2011]
    • (2008) Measuring Medicine Prices, Availability, Affordability and Price Components
  • 29
    • 79958068487 scopus 로고    scopus 로고
    • Differences in the availability of medicines for chronic and acute conditions in the public and private sectors of developing countries
    • A. Cameron, I. Roubos, M. Ewen Differences in the availability of medicines for chronic and acute conditions in the public and private sectors of developing countries Bull World Health Org 89 2011 412 421
    • (2011) Bull World Health Org , vol.89 , pp. 412-421
    • Cameron, A.1    Roubos, I.2    Ewen, M.3
  • 34
    • 67650898263 scopus 로고    scopus 로고
    • Analysis of global strategies to reduce the price of antiretroviral medicines: Evidence from transactional database
    • B. Waning, W. Kaplan, A.C. King Analysis of global strategies to reduce the price of antiretroviral medicines: evidence from transactional database Bull World Health Org 87 2009 520 528
    • (2009) Bull World Health Org , vol.87 , pp. 520-528
    • Waning, B.1    Kaplan, W.2    King, A.C.3
  • 35
    • 0010974824 scopus 로고    scopus 로고
    • International Monetary Fund International Monetary Fund Washington, DC [Accessed November 9, 2010]
    • International Monetary Fund World Economic Outlook Database 2011 International Monetary Fund Washington, DC http://www.imf.org/external/pubs/ft/ weo/2007/01/data/index.aspx [Accessed November 9, 2010]
    • (2011) World Economic Outlook Database
  • 36
    • 70349580829 scopus 로고    scopus 로고
    • United Nations, Department of Economic and Social Affairs, Population Division, Population Estimates and Projections Section Updated June 28, 2011 [Accessed March 27, 2012]
    • United Nations, Department of Economic and Social Affairs, Population Division, Population Estimates and Projections Section World population prospects, the 2010 revision Updated June 28, 2011 http://esa.un.org/unpd/wpp/ Excel-Data/population.htm [Accessed March 27, 2012]
    • World Population Prospects, the 2010 Revision
  • 37
    • 84864605669 scopus 로고    scopus 로고
    • Center for Health Services and Technology Research, National Institute of Health Research and Development, Ministry of Health Indonesia [Accessed November 8, 2011]
    • Center for Health Services and Technology Research, National Institute of Health Research and Development, Ministry of Health Indonesia The prices people have to pay for medicines in Indonesia http://www.haiweb.org/medicineprices/ surveys/200408ID/survey-report.pdf 2005 [Accessed November 8, 2011]
    • (2005) The Prices People Have to Pay for Medicines in Indonesia
  • 42
    • 84864594554 scopus 로고    scopus 로고
    • Organisation Mondiale de la Santé, Caisse Nationale des Organismes de Prévoyance Sociale Ministère de la Santé, Fédération Nationale des Pharmaciens, Conseil National de l'Ordre des Pharmaciens Maroc. Avril 2004 [Accessed November 8, 2011]
    • Organisation Mondiale de la Santé, Caisse Nationale des Organismes de Prévoyance Sociale Ministère de la Santé, Fédération Nationale des Pharmaciens, Conseil National de l'Ordre des Pharmaciens Enquête sur les Prix des Médicaments Maroc. Avril 2004 http://www.haiweb.org/medicineprices/surveys/200404MA/survey-report.pdf [Accessed November 8, 2011]
    • Enquête sur les Prix des Médicaments
  • 44
    • 78650221146 scopus 로고    scopus 로고
    • The Network for Consumer Protection [Accessed November 8, 2011]
    • The Network for Consumer Protection Prices, availability and affordability of medicines in Pakistan http://www.haiweb.org/medicineprices/ surveys/200407PK/survey-report.pdf 2006 [Accessed November 8, 2011]
    • (2006) Prices, Availability and Affordability of Medicines in Pakistan
  • 46
    • 33745121237 scopus 로고    scopus 로고
    • Price competition in the Chinese pharmaceutical market
    • Y.R. Wang Price competition in the Chinese pharmaceutical market Int J Health Care Fin Econ 6 2006 119 129
    • (2006) Int J Health Care Fin Econ , vol.6 , pp. 119-129
    • Wang, Y.R.1
  • 47
    • 77954736394 scopus 로고    scopus 로고
    • Prices, availability and affordability of essential medicines in rural areas of Hubei Province, China
    • H. Yang, H.H. Dib, M. Zhu Prices, availability and affordability of essential medicines in rural areas of Hubei Province, China Health Pol Plan 25 2010 219 229
    • (2010) Health Pol Plan , vol.25 , pp. 219-229
    • Yang, H.1    Dib, H.H.2    Zhu, M.3
  • 49
    • 0036689918 scopus 로고    scopus 로고
    • Encouraging the use of generic medicines: Implications for transition economies
    • D.R. King, P. Kanavos Encouraging the use of generic medicines: implications for transition economies Cro Med J 43 2002 462 469
    • (2002) Cro Med J , vol.43 , pp. 462-469
    • King, D.R.1    Kanavos, P.2
  • 50
    • 0034752750 scopus 로고    scopus 로고
    • Impact of the minimum pricing policy and introduction of brand (generic) substitution into the Pharmaceutical Benefits Scheme in Australia
    • P. McManus, D.J. Birkett, J. Dudley, A. Stevens Impact of the minimum pricing policy and introduction of brand (generic) substitution into the Pharmaceutical Benefits Scheme in Australia Pharmacoepidemiol Drug Safety 10 2001 295 300
    • (2001) Pharmacoepidemiol Drug Safety , vol.10 , pp. 295-300
    • McManus, P.1    Birkett, D.J.2    Dudley, J.3    Stevens, A.4
  • 53
    • 84864633138 scopus 로고    scopus 로고
    • The WHO Expert Committee on Specifications for Pharmaceutical Preparations Geneva, Switzerland: World Health Organization, no date
    • The WHO Expert Committee on Specifications for Pharmaceutical Preparations. Quality Assurance of Pharmaceuticals: Meeting a Major Public Health Challenge. Geneva, Switzerland: World Health Organization, no date.
    • Quality Assurance of Pharmaceuticals: Meeting A Major Public Health Challenge
  • 54
    • 77949284499 scopus 로고    scopus 로고
    • Understanding therapeutic equivalence in epilepsy
    • R. Sankar, T.A. Glauser Understanding therapeutic equivalence in epilepsy CNS Spectrums 15 2012 112 123
    • (2012) CNS Spectrums , vol.15 , pp. 112-123
    • Sankar, R.1    Glauser, T.A.2
  • 55
    • 0035964225 scopus 로고    scopus 로고
    • Buy some today: Can generics be safely substituted for brand-name drugs?
    • R.P. Lesser, G. Krauss Buy some today: can generics be safely substituted for brand-name drugs? Neurology 57 2001 571 573
    • (2001) Neurology , vol.57 , pp. 571-573
    • Lesser, R.P.1    Krauss, G.2
  • 56
    • 32344435090 scopus 로고    scopus 로고
    • Generic substitution of antihypertensive drugs: Does it affect adherence?
    • B.L. Van Wijk, O.H. Klungel, E.R. Heerdink, A. de Boer Generic substitution of antihypertensive drugs: does it affect adherence? Ann Pharmacother 40 2006 15 20
    • (2006) Ann Pharmacother , vol.40 , pp. 15-20
    • Van Wijk, B.L.1    Klungel, O.H.2    Heerdink, E.R.3    De Boer, A.4
  • 57
    • 19044401085 scopus 로고    scopus 로고
    • What are the obstacles to generic substitution? An assessment of the behaviour of prescribers, patients and pharmacies during the first year of generic substitution in Sweden
    • K. Andersson, C. Sonesson, M. Petzold What are the obstacles to generic substitution? An assessment of the behaviour of prescribers, patients and pharmacies during the first year of generic substitution in Sweden Pharmacoepidemiol Drug Safety 14 2005 341 348
    • (2005) Pharmacoepidemiol Drug Safety , vol.14 , pp. 341-348
    • Andersson, K.1    Sonesson, C.2    Petzold, M.3
  • 58
    • 67649273394 scopus 로고    scopus 로고
    • Pharmaceutical Pricing Policies in a Global Market
    • Organization for Economic Co-operation and Development Organization for Economic Co-operation and Development Paris, France
    • Organization for Economic Co-operation and Development Pharmaceutical Pricing Policies in a Global Market OECD Health Policy Studies 2008 Organization for Economic Co-operation and Development Paris, France
    • (2008) OECD Health Policy Studies
  • 59
    • 80051966985 scopus 로고    scopus 로고
    • IMS Institute for Healthcare Informatics IMS Health Incorporated and its affiliates New Jersey
    • IMS Institute for Healthcare Informatics The Use of Medicines in the United States: Review of 2010 2011 IMS Health Incorporated and its affiliates New Jersey
    • (2011) The Use of Medicines in the United States: Review of 2010
  • 60
    • 42149162431 scopus 로고    scopus 로고
    • The impact of generic substitution on price competition in Finland
    • V. Aalto-Setälä The impact of generic substitution on price competition in Finland Eur J Health Econ 9 2008 185 191
    • (2008) Eur J Health Econ , vol.9 , pp. 185-191
    • Aalto-Setälä, V.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.